<DOC>
	<DOCNO>NCT00138723</DOCNO>
	<brief_summary>This Phase 3 trial investigate efficacy , tolerability safety fesoterodine fumarate ( SR ) ( fesoterodine ; SPM 907 ) adult male female subject overactive bladder syndrome . The trial randomize , double-blind placebo control multicenter trial . The trial consist 2 week Run-In period , 12 week double-blind Treatment period 2 week Safety Follow-Up period . Subjects randomize one 3 treatment arm receive either fesoterodine fumarate 4mg , fesoterodine fumarate 8mg , placebo double-blind Treatment period . Two primary efficacy variable assess submission United States : change average number micturition ( frequency ) per 24 hour change average number urge incontinence episode per 24 hour . For submission European Union , first primary variable change average number micturition ( frequency ) per 24 hour co-primary variable treatment response , base treatment benefit scale . All continuous variable measure change baseline value 12 week treatment . The following safety variable observe assessed : adverse event , change residual urinary volume ( mL ) , change laboratory parameter , change vital sign , change electrocardiogram ( ECG ) , change physical examination change urological/urogynecological examination .</brief_summary>
	<brief_title>Trial Investigate Efficacy , Tolerability Safety Fesoterodine Sustained Release Subjects With Overactive Bladder Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Overactive bladder syndrome Less 8 micturition 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>